Skip to main content

Advertisement

SpringerLink
Log in

Patients’ access to biologics in rheumatoid arthritis: a comparison between Portugal and other European countries

  • Original Article
  • Published:
The European Journal of Health Economics Aims and scope Submit manuscript

Abstract

Background

Despite the widespread availability of biologics across Europe, rheumatoid arthritis (RA) patients’ access to these drugs differs significantly among countries.

Objectives

To compare the proportion of RA patients treated with biologics across Europe and investigate the factors that most influence it, with focus on the Portuguese case, reportedly with low access rates to biologics.

Methods

The biologics’ market was characterized for 15 selected European countries. Variables potentially influencing patients’ access to biologics (PAB) in RA were also collected, including demographic, disease, economic, funding and biologics’ market-related data. A multivariable regression model identified the factors that best explain PAB. Based on these determinants, a cluster analysis was performed to group the countries with most similar behaviour regarding PAB allowing the evaluation of Portugal’s relative position among these countries.

Results

The regression model (R 2 = 0.953) indicated that PAB in selected countries is explained mostly by its gross domestic product (GDP) per capita, the usage of methotrexate (MTX) and the biologics’ distribution channel. Current MTX usage in Portugal shows similarity with practice from UK, France, Germany or Spain 5 years before, explaining why PAB in Portugal stood at 7 % in 2010, 12 percentage points below the average of selected countries.

Conclusions

Variations in RA PAB were found across selected countries with Portugal showing the lowest proportion. GDP per capita, biologics distribution channel and consumption of MTX appear to be the best explanatory factors for these fluctuations in European countries.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Chen, Y.F., Jobanputra, P., Barton, P., et al.: A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness. Health Technol. Assess. 10(42), 3–4 (2006)

    Google Scholar 

  2. Kvien, T.K.: Epidemiology and burden of illness of rheumatoid arthritis. Pharmacoeconomics 22, 1–12 (2004)

    Article  PubMed  Google Scholar 

  3. Matos, A.A., Branco, J.C., Canas Silva, J., Viana Queiroz, M., Pádua, F.: Inquérito epidemiológico de doenças reumáticas numa amostra da população portuguesa (resultados preliminares). Acta Reumatol. Port. 16(1), 98 (1991)

  4. National Institute for Health and Clinical Excellence: Rheumatoid arthritis—National clinical guideline for management and treatment in adults. NICE, London (2009)

    Google Scholar 

  5. Singh, J.A., Christensen, R., Wells, G.A., et al.: Biologics for rheumatoid arthritis: an overview of Cochrane reviews (Review). Cochrane Database Syst. Rev. (4) (2009). doi:10.1002/14651858.CD007848.pub2

  6. Smolen, J.S., Landewé, R., Breedveld, F.C., et al.: EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann. Rheum. Dis. 69(6), 964–975 (2010). doi:10.1136/ard.2009.126532

    Article  PubMed  CAS  Google Scholar 

  7. Jönsson, B., Kobelt, G., Smolen, J.: The burden of rheumatoid arthritis and access to treatment: uptake of new therapies. Eur. J. Health Econ. 8, 61–86 (2008). doi:10.1007/s10198-007-0089-7

    Article  Google Scholar 

  8. Kobelt, G., Kasteng, F.: Access to innovative treatments in rheumatoid arthritis in Europe. A report prepared for the European Federation of Pharmaceutical Industry Associations (EFPIA). http://www.lif.se/default.aspx?id=44400 (2009). Accessed December 2011

  9. Miltenburger, C., Gunther, O., Justo, N., et al.: A survey of barriers to treatment access in rheumatoid arthritis in France, Germany, Italy, Spain and the UK (2009). Accessed December 2011

  10. Emery, P., Van Vollenhoven, R., Ostergaard, M., et al.: Guidelines for initiation of anti-tumour necrosis factor therapy in rheumatoid arthritis: similarities and differences across Europe. Ann. Rheum. Dis. 68(4), 456–459 (2009). doi:10.1136/ard.2008.100362

    Article  PubMed  CAS  Google Scholar 

  11. Cruz, M., Fonseca, J.E., Branco, J.C.: Artrite reumatóide: paradigma das doenças reumáticas crónicas. Tecnologia Médica 2, 2–11 (2002)

    Google Scholar 

  12. Cruz, M., Fonseca, J.E., Branco, J.C.: Três anos de administração de etanercept e infliximab a doentes com artrite reumatóide refractária—avaliação clínica e radiográfica e segurança. Acta Reumatol. Port. 29, 21–32 (2004)

    Google Scholar 

  13. Barcelos, A., Salvador, M.J., da Silva, J.A., et al.: Indução de auto anticorpos durante tratamento prolongado com infliximab em doentes com artrite reumatóide. Acta Reumatol. Port. 29, 161–167 (2004)

    Google Scholar 

  14. Grupo de Estudos de Artrite Reumatóide da Sociedade Portuguesa de Reumatologia: Análise de 376 doentes com Artrite Reumatóide submetidos a terapêutica biológica registados na base de dados de agentes biológicos da Sociedade Portuguesa de Reumatologia. Acta Reumatol. Port. 30, 63–71 (2005)

    Google Scholar 

  15. Canhão, H., Faustino, A., Martins, F., et al.: Reuma.pt—the rheumatic diseases portuguese register. Acta Reumatol. Port. 36(1), 45–56 (2011)

    PubMed  Google Scholar 

  16. WHO Collaborating Centre for Drug Statistics Methodology: WHODD guidelines for ATC classification and DDD assignment 2010. Norwegian Institute of Public Health. http://www.whocc.no/atc_ddd_index (2010). Accessed January 2011

  17. United Nations Development Programme: Human Development Report 2007/2008. http://hdrstats.undp.org/en/indicators/default.html (2007)

  18. United Nations Development Programme: Human Development Report 2010. http://hdr.undp.org/en/reports/global/hdr2010/chapters/ (2010)

  19. Eurostat database Directorate-General (DG) of the European Commission. http://epp.eurostat.ec.europa.eu (1953)

  20. World Economic Outlook Database, April 2011. International Monetary Fund. http://www.imf.org/external/pubs/ft/weo/2011/01/weodata/weoselgr.aspx (2011). Accessed April 2011

  21. Observatório Do Medicamento e Produtos de Saúde: Consumo de Medicamentos em meio hospitalar. In. INFARMED (2010)

  22. MIDAS Database. IMS Health. Accessed January 2011

  23. Orlewska, E., Ancuta, I., Anic, B., et al.: Access to biologic treatment for rheumatoid arthritis in Central and Eastern European (CEE) countries. Med. Sci. Monit. 17(4), SR1–SR13 (2011)

    Article  PubMed  Google Scholar 

  24. Rousseeuw, P.J.: Silhouettes: a graphical aid to the interpretation and validation of cluster analysis. Computational and applied mathematics. J. Comput. Appl. Math. (1987). doi:10.1016/0377-0427(87)90125-7

    Google Scholar 

  25. Associação Nacional dos Doentes com Artrite Reumatóide: Impacto dos medicamentos biológicos na qualidade de vida dos doentes. Paper presented at the Plataforma Mais Saúde, INFARMED, Portugal, 22 Nov 2011

  26. Cunha-Miranda, L., Santos, H., Ferreira, J., et al.: Finding Rheumatoid Arthritis Impact on Life (FRAIL Study): economic burden. Acta Reumatol. Port. (37), 134–142 (2012)

  27. Gulácsi, L.: Future challenges for health economics and health technology assessment of biological drugs. Eur. J. Health Econ. 11(3), 235–238 (2010). doi:10.1007/s10198-010-0246-2

    Article  PubMed  Google Scholar 

  28. Ramiro, S., Canhão, H., Branco, J.C.: EpiReumaPt protocol—Portuguese epidemiologic study of the rheumatic diseases. Acta Reumatol. Port. 35(3), 384–390 (2010)

    PubMed  Google Scholar 

  29. Drosos, A.A., Lanchbury, J.S., Panayi, G.S., et al.: Rheumatoid arthritis in greek and british patients. A comparative clinical, radiologic, and serologic study. Arthritis Rheum. 35(7), 745–748 (1992). doi:10.1002/art.1780350705

    Google Scholar 

  30. Salvarani, C., Macchioni, P.L., Mantovani, W., et al.: HLA-DRB1 alleles associated with rheumatoid arthritis in northern Italy: correlation with disease severity. Br. J. Rheumatol. 37, 165–169 (1998)

    Article  PubMed  CAS  Google Scholar 

  31. Ronda, E., Ruiz, M.T., Pascual, E., et al.: Differences between Spanish and British patients in the severity of rheumatoid arthritis: comment on the article by Drosos et al. Arthritis Rheum. 37(1), 147–148 (1994). doi:10.1002/art.1780370125

    Article  PubMed  CAS  Google Scholar 

  32. Benazet, J.F., Reviron, D., Mercier, D., et al.: HLADRB1 alleles associated with rheumatoid arthritis in southern France: absence of extraarticular disease despite expression of the shared epitope. J. Rheumatol. 22, 607–610 (1995)

    PubMed  CAS  Google Scholar 

Download references

Acknowledgements

The authors would like to thank Luís Veloso for critical review of this paper. The study was funded by Merck Sharp & Dohme.

Author information

Authors and Affiliations

  1. Outcomes Research, Merck Sharp & Dohme, Edificio Vasco da Gama, nº 19 , 2770-192, Paço de Arcos, Portugal

    P. A. Laires & A. P. Martins

  2. IMS Health, Oeiras, Portugal

    F. Exposto

  3. Medical Affairs, Merck Sharp & Dohme, Oeiras, Portugal

    R. Mesquita

  4. Department of Rheumatology, Instituto Português de Reumatologia, Lisbon, Portugal

    L. Cunha-Miranda

  5. Rheumatology Research Unit, Instituto de Medicina Molecular da Faculdade de Medicina da Universidade de Lisboa, Lisbon, Portugal

    J. E. Fonseca

Authors
  1. P. A. Laires
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. F. Exposto
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. R. Mesquita
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A. P. Martins
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. L. Cunha-Miranda
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. J. E. Fonseca
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to P. A. Laires.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Laires, P.A., Exposto, F., Mesquita, R. et al. Patients’ access to biologics in rheumatoid arthritis: a comparison between Portugal and other European countries. Eur J Health Econ 14, 875–885 (2013). https://doi.org/10.1007/s10198-012-0432-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10198-012-0432-5

Keywords

JEL Classification

Search

Navigation